The antagonism between MCT-1 and p53 affects the tumorigenic outcomes

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Kasiappan, Ravi ^a   Shih, Hung Ju ^a,b   Wu, Meng Hsun ^a   Choy, ChikOn ^a   Lin, Tai Du ^a   Chen, Linyi ^b   Hsu, Hsin Ling ^a  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b NATIONAL TSING HUA UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN; PROTEIN MCT 1; PROTEIN MDM2; PROTEIN P53; PROTEIN PIRH2; UBIQUITIN PROTEIN LIGASE COP1; UNCLASSIFIED DRUG; CELL CYCLE PROTEIN; MCTS1 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARCINOGENICITY; CONTROLLED STUDY; GENOTOXICITY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; ONCOGENE MCT 1; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RNA METABOLISM; RNA STABILITY; TRANSCRIPTION REGULATION; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; ANIMAL; BAGG ALBINO MOUSE; CELL MOTION; CHROMATIN IMMUNOPRECIPITATION; FEMALE; GEL MOBILITY SHIFT ASSAY; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SITE DIRECTED MUTAGENESIS; TUMOR CELL LINE;

MUS;

ANIMALS; APOPTOSIS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL MOVEMENT; CHROMATIN IMMUNOPRECIPITATION; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED BALB C; MUTAGENESIS, SITE-DIRECTED; ONCOGENE PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 78649760150     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-311     Document Type: Article

References (64)

1. Sherr CJ. Principles of tumor suppression. Cell 2004, 116:235-246. 10.1016/S0092-8674(03)01075-4, 14744434.
2. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004, 10:789-799. 10.1038/nm1087, 15286780.
3. Soussi T, Lozano G. p53 mutation heterogeneity in cancer. Biochem Biophys Res Commun 2005, 331:834-842. 10.1016/j.bbrc.2005.03.190, 15865939.
4. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000, 408:307-310. 10.1038/35042675, 11099028.
5. Vousden KH, Lane DP. p53 in health and disease. Nat Rev Mol Cell Biol 2007, 8:275-283. 10.1038/nrm2147, 17380161.
6. el-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B. Definition of a consensus binding site for p53. Nat Genet 1992, 1:45-49. 10.1038/ng0492-45, 1301998.
7. Gottlieb TM, Oren M. p53 in growth control and neoplasia. Biochim Biophys Acta 1996, 1287:77-102.
8. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997, 88:323-331. 10.1016/S0092-8674(00)81871-1, 9039259.
9. Leng RP, Lin Y, Ma W, Wu H, Lemmers B, Chung S, Parant JM, Lozano G, Hakem R, Benchimol S. Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell 2003, 112:779-791. 10.1016/S0092-8674(03)00193-4, 12654245.
10. Dornan D, Wertz I, Shimizu H, Arnott D, Frantz GD, Dowd P, O'Rourke K, Koeppen H, Dixit VM. The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature 2004, 429:86-92. 10.1038/nature02514, 15103385.
11. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 1993, 75:817-825. 10.1016/0092-8674(93)90500-P, 8242752.
12. Barak Y, Juven T, Haffner R, Oren M. mdm2 expression is induced by wild type p53 activity. EMBO J 1993, 12:461-468. 413229, 8440237.
13. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995, 80:293-299. 10.1016/0092-8674(95)90513-8, 7834749.
14. Morris GF, Bischoff JR, Mathews MB. Transcriptional activation of the human proliferating-cell nuclear antigen promoter by p53. Proc Natl Acad Sci USA 1996, 93:895-899. 10.1073/pnas.93.2.895, 40154, 8570655.
15. Li M, Brooks CL, Wu-Baer F, Chen D, Baer R, Gu W. Mono- versus polyubiquitination: differential control of p53 fate by Mdm2. Science 2003, 302:1972-1975. 10.1126/science.1091362, 14671306.
16. Cawley S, Bekiranov S, Ng HH, Kapranov P, Sekinger EA, Kampa D, Piccolboni A, Sementchenko V, Cheng J, Williams AJ, et al. Unbiased mapping of transcription factor binding sites along human chromosomes 21 and 22 points to widespread regulation of noncoding RNAs. Cell 2004, 116:499-509. 10.1016/S0092-8674(04)00127-8, 14980218.
17. Wei CL, Wu Q, Vega VB, Chiu KP, Ng P, Zhang T, Shahab A, Yong HC, Fu Y, Weng Z, et al. A global map of p53 transcription-factor binding sites in the human genome. Cell 2006, 124:207-219. 10.1016/j.cell.2005.10.043, 16413492.
18. Kim E, Giese A, Deppert W. Wild-type p53 in cancer cells: when a guardian turns into a blackguard. Biochem Pharmacol 2009, 77:11-20. 10.1016/j.bcp.2008.08.030, 18812169.
19. Janicke RU, Sohn D, Schulze-Osthoff K. The dark side of a tumor suppressor: anti-apoptotic p53. Cell Death Differ 2008, 15:959-976. 10.1038/cdd.2008.33, 18356920.
20. Sharpless NE, DePinho RA. p53: good cop/bad cop. Cell 2002, 110:9-12. 10.1016/S0092-8674(02)00818-8, 12150992.
21. Vousden KH. Outcomes of p53 activation--spoilt for choice. J Cell Sci 2006, 119:5015-5020. 10.1242/jcs.03293, 17158908.
22. Essmann F, Pohlmann S, Gillissen B, Daniel PT, Schulze-Osthoff K, Janicke RU. Irradiation-induced translocation of p53 to mitochondria in the absence of apoptosis. J Biol Chem 2005, 280:37169-37177. 10.1074/jbc.M502052200, 16148012.
23. Budanov AV, Sablina AA, Feinstein E, Koonin EV, Chumakov PM. Regeneration of peroxiredoxins by p53-regulated sestrins, homologs of bacterial AhpD. Science 2004, 304:596-600. 10.1126/science.1095569, 15105503.
24. Sablina AA, Budanov AV, Ilyinskaya GV, Agapova LS, Kravchenko JE, Chumakov PM. The antioxidant function of the p53 tumor suppressor. Nat Med 2005, 11:1306-1313. 10.1038/nm1320, 2637821, 16286925.
25. Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R, Gottlieb E, Vousden KH. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 2006, 126:107-120. 10.1016/j.cell.2006.05.036, 16839880.
26. Shi B, Hsu HL, Evens AM, Gordon LI, Gartenhaus RB. Expression of the candidate MCT-1 oncogene in B- and T-cell lymphoid malignancies. Blood 2003, 102:297-302. 10.1182/blood-2002-11-3486, 12637315.
27. Dai B, Zhao XF, Hagner P, Shapiro P, Mazan-Mamczarz K, Zhao S, Natkunam Y, Gartenhaus RB. Extracellular signal-regulated kinase positively regulates the oncogenic activity of MCT-1 in diffuse large B-cell lymphoma. Cancer Res 2009, 69:7835-7843. 10.1158/0008-5472.CAN-09-1606, 2839501, 19789340.
28. Dierov J, Prosniak M, Gallia G, Gartenhaus RB. Increased G1 cyclin/cdk activity in cells overexpressing the candidate oncogene, MCT-1. J Cell Biochem 1999, 74:544-550. 10.1002/(SICI)1097-4644(19990915)74:4<544::AID-JCB4>3.0.CO;2-4, 10440924.
29. Prosniak M, Dierov J, Okami K, Tilton B, Jameson B, Sawaya BE, Gartenhaus RB. A novel candidate oncogene, MCT-1, is involved in cell cycle progression. Cancer Res 1998, 58:4233-4237.
30. Hsu HL, Shi B, Gartenhaus RB. The MCT-1 oncogene product impairs cell cycle checkpoint control and transforms human mammary epithelial cells. Oncogene 2005, 24:4956-4964. 10.1038/sj.onc.1208680, 15897892.
31. Levenson AS, Thurn KE, Simons LA, Veliceasa D, Jarrett J, Osipo C, Jordan VC, Volpert OV, Satcher RL, Gartenhaus RB. MCT-1 oncogene contributes to increased in vivo tumorigenicity of MCF7 cells by promotion of angiogenesis and inhibition of apoptosis. Cancer Res 2005, 65:10651-10656. 10.1158/0008-5472.CAN-05-0845, 16322206.
32. Fleischer TC, Weaver CM, McAfee KJ, Jennings JL, Link AJ. Systematic identification and functional screens of uncharacterized proteins associated with eukaryotic ribosomal complexes. Genes Dev 2006, 20:1294-1307. 10.1101/gad.1422006, 1472904, 16702403.
33. Mazan-Mamczarz K, Hagner PR, Corl S, Srikantan S, Wood WH, Becker KG, Gorospe M, Keene JD, Levenson AS, Gartenhaus RB. Post-transcriptional gene regulation by HuR promotes a more tumorigenic phenotype. Oncogene 2008, 27:6151-6163. 10.1038/onc.2008.215, 2575016, 18641687.
34. Reinert LS, Shi B, Nandi S, Mazan-Mamczarz K, Vitolo M, Bachman KE, He H, Gartenhaus RB. MCT-1 protein interacts with the cap complex and modulates messenger RNA translational profiles. Cancer Res 2006, 66:8994-9001. 10.1158/0008-5472.CAN-06-1999, 16982740.
35. Hsu HL, Choy CO, Kasiappan R, Shih HJ, Sawyer JR, Shu CL, Chu KL, Chen YR, Hsu HF, Gartenhaus RB. MCT-1 oncogene downregulates p53 and destabilizes genome structure in the response to DNA double-strand damage. DNA Repair (Amst) 2007, 6:1319-1332. 10.1016/j.dnarep.2007.02.028, 17416211.
36. Kasiappan R, Shih HJ, Chu KL, Chen WT, Liu HP, Huang SF, Choy CO, Shu CL, Din R, Chu JS, Hsu HL. Loss of p53 and MCT-1 overexpression synergistically promote chromosome instability and tumorigenicity. Mol Cancer Res 2009, 7:536-548. 10.1158/1541-7786.MCR-08-0422, 19372582.
37. Wang S, El-Deiry WS. p73 or p53 directly regulates human p53 transcription to maintain cell cycle checkpoints. Cancer Res 2006, 66:6982-6989. 10.1158/0008-5472.CAN-06-0511, 16849542.
38. Sun X, Shimizu H, Yamamoto K. Identification of a novel p53 promoter element involved in genotoxic stress-inducible p53 gene expression. Mol Cell Biol 1995, 15:4489-4496. 230688, 7623839.
39. Roger L, Gadea G, Roux P. Control of cell migration: a tumour suppressor function for p53?. Biol Cell 2006, 98:141-152. Review, 10.1042/BC20050058, 16480340.
40. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997, 387:296-299. 10.1038/387296a0, 9153395.
41. Dornan D, Bheddah S, Newton K, Ince W, Frantz GD, Dowd P, Koeppen H, Dixit VM, French DM. COP1, the negative regulator of p53, is overexpressed in breast and ovarian adenocarcinomas. Cancer Res 2004, 64:7226-7230. 10.1158/0008-5472.CAN-04-2601, 15492238.
42. Ganguli G, Wasylyk B. p53-independent functions of MDM2. Mol Cancer Res 2003, 1:1027-1035.
43. Wang XM, Yang LY, Guo L, Fan C, Wu F. p53-induced RING-H2 protein, a novel marker for poor survival in hepatocellular carcinoma after hepatic resection. Cancer 2009, 115:4554-4563. 10.1002/cncr.24494, 19551892.
44. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992, 69:1237-1245. 10.1016/0092-8674(92)90644-R, 1535557.
45. Wu X, Bayle JH, Olson D, Levine AJ. The p53-mdm-2 autoregulatory feedback loop. Genes Dev 1993, 7:1126-1132. 10.1101/gad.7.7a.1126, 8319905.
46. Shiota M, Izumi H, Onitsuka T, Miyamoto N, Kashiwagi E, Kidani A, Hirano G, Takahashi M, Naito S, Kohno K. Twist and p53 reciprocally regulate target genes via direct interaction. Oncogene 2008, 27:5543-5553. 10.1038/onc.2008.176, 18504427.
47. Kim MK, Carroll WL. Autoregulation of the N-myc gene is operative in neuroblastoma and involves histone deacetylase 2. Cancer 2004, 101:2106-2115. 10.1002/cncr.20626, 15382088.
48. Sivak LE, Tai KF, Smith RS, Dillon PA, Brodeur GM, Carroll WL. Autoregulation of the human N-myc oncogene is disrupted in amplified but not single-copy neuroblastoma cell lines. Oncogene 1997, 15:1937-1946. 10.1038/sj.onc.1201363, 9365240.
49. Weaver BA, Cleveland DW. Does aneuploidy cause cancer?. Curr Opin Cell Biol 2006, 18:658-667. 10.1016/j.ceb.2006.10.002, 17046232.
50. Nikolopoulos SN, Blaikie P, Yoshioka T, Guo W, Giancotti FG. Integrin beta4 signaling promotes tumor angiogenesis. Cancer Cell 2004, 6:471-483. 10.1016/j.ccr.2004.09.029, 15542431.
51. Giehl K. Oncogenic Ras in tumour progression and metastasis. Biol Chem 2005, 386:193-205. 10.1515/BC.2005.025, 15843165.
52. Yang MH, Wu KJ. TWIST activation by hypoxia inducible factor-1 (HIF-1): implications in metastasis and development. Cell Cycle 2008, 7:2090-2096. 10.4161/cc.7.14.6324, 18635960.
53. Yang MH, Wu MZ, Chiou SH, Chen PM, Chang SY, Liu CJ, Teng SC, Wu KJ. Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nat Cell Biol 2008, 10:295-305. 10.1038/ncb1691, 18297062.
54. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, Simons JW. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 1999, 59:5830-5835.
55. Shangary S, Wang S. Targeting the MDM2-p53 interaction for cancer therapy. Clin Cancer Res 2008, 14:5318-5324. 10.1158/1078-0432.CCR-07-5136, 2676446, 18765522.
56. Duarte ML, de Moraes E, Pontes E, Schluckebier L, de Moraes JL, Hainaut P, Ferreira CG. Role of p53 in the induction of cyclooxygenase-2 by cisplatin or paclitaxel in non-small cell lung cancer cell lines. Cancer Lett 2009, 279:57-64. 10.1016/j.canlet.2009.01.021, 19217709.
57. el-Deiry WS. Regulation of p53 downstream genes. Semin Cancer Biol 1998, 8:345-357. 10.1006/scbi.1998.0097, 10101800.
58. de Moraes E, Dar NA, de Moura Gallo CV, Hainaut P. Cross-talks between cyclooxygenase-2 and tumor suppressor protein p53: Balancing life and death during inflammatory stress and carcinogenesis. Int J Cancer 2007, 121:929-937. 10.1002/ijc.22899, 17582597.
59. Nieminen AL, Qanungo S, Schneider EA, Jiang BH, Agani FH. Mdm2 and HIF-1alpha interaction in tumor cells during hypoxia. J Cell Physiol 2005, 204:364-369. 10.1002/jcp.20406, 15880652.
60. Carroll VA, Ashcroft M. Regulation of angiogenic factors by HDM2 in renal cell carcinoma. Cancer Res 2008, 68:545-552. 10.1158/0008-5472.CAN-06-4738, 18199551.
61. Cairns CA, White RJ. p53 is a general repressor of RNA polymerase III transcription. EMBO J 1998, 17:3112-3123. 10.1093/emboj/17.11.3112, 1170650, 9606193.
62. Felton-Edkins ZA, Kenneth NS, Brown TR, Daly NL, Gomez-Roman N, Grandori C, Eisenman RN, White RJ. Direct regulation of RNA polymerase III transcription by RB, p53 and c-Myc. Cell Cycle 2003, 2:181-184.
63. Stein T, Crighton D, Boyle JM, Varley JM, White RJ. RNA polymerase III transcription can be derepressed by oncogenes or mutations that compromise p53 function in tumours and Li-Fraumeni syndrome. Oncogene 2002, 21:2961-2970. 10.1038/sj.onc.1205372, 12082526.
64. White RJ. RNA polymerase III transcription and cancer. Oncogene 2004, 23:3208-3216. 10.1038/sj.onc.1207547, 15094770.